Combat Medical £2.6m seed funds heated bladder chemotherapy trial avoiding cystectomy
This article covers Combat Medical, a healthtech startup, which has raised £2.6m in a seed funding round to advance its HIVEC hyperthermic intravesical chemotherapy system into a pivotal phase 3 trial aimed at securing FDA registration for patients with BCG-unresponsive non-muscle-invasive bladder cancer. The funding supports the registration trial and related clinical and commercial activity targeting this patient group and US regulatory approval.
Combat Medical, a healthtech startup, has raised £2.6 million in a seed funding round to advance its hyperthermic intravesical chemotherapy system, HIVEC, through a pivotal phase 3 trial aimed at securing FDA registration for patients with BCG-unresponsive non-muscle-invasive bladder cancer.
Why it matters
The announcement matters because it targets a clear clinical gap. Patients whose disease does not respond to Bacillus Calmette-Guérin, or BCG, currently face radical cystectomy — removal of the bladder — as the usual next step. If HIVEC demonstrates safety and efficacy in a registration trial, it could offer a bladder-preserving alternative and change treatment pathways for those patients. The financing also underlines the capital intensity of medical-device clinical programmes that pursue US regulatory approval.
Inside the product
HIVEC is a device-assisted hyperthermic intravesical chemotherapy treatment. It delivers heated chemotherapy directly into the bladder, with the intent of improving drug uptake and tolerability compared with standard intravesical chemotherapy alone. Combat Medical also develops HIPEC technology for peritoneal cancers, where hyperthermic chemotherapy is applied in the abdominal cavity during surgery.
Combat reports an installed base of more than 350 systems and says clinicians have completed over 100,000 HIVEC treatments to date. The company plans to use the new funds to support its HIVEC HEAT FDA registration trial and to expand clinical programmes for bladder and peritoneal cancers ahead of a US market entry.
Who are the investors?
The first close of the round was led by T&J Meyer Family Foundation and included investments from Varia Ventures, NW Angel Fund and a group of family offices and individual, non-institutional investors. The financing will underwrite the ongoing pivotal trial and support further clinical and commercial activity as Combat pursues regulatory approval in the US.
Balint Nemeth, T&J Meyer Family Foundation, added:
Combat Medical is leading the development and clinical use of device assisted therapies with potential to disrupt current treatment standards. With systems in wide clinical use and already impacting patient outcomes, we are excited to support the company as HIVEC progresses through clinical trials.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
Edward Bruce-White, Chief Executive Officer of Combat Medical, said:
Our installed base of over 350 systems and the completion of over 100,000 HIVEC treatments to date demonstrates efficacy and use as a safe and well-tolerated, bladder-sparing alternative to radical cystectomy in BCG-unresponsive, high-risk NMIBC. Setting a new standard for patient care, it also provides clinicians and payers with advanced, affordable options that can easily be built into current treatment pathways. We are proud to have our investors on board as we progress through to FDA approval.
The company says further financings will be sought to complete FDA registration, grow operations and accelerate US market entry.
The bigger picture
Device-led oncology therapies require both clinical evidence and capital to move from established regional use to global markets. Combat’s fundraising follows a broader trend of UK healthtech companies targeting US regulatory pathways to reach larger payer markets. The deal also reflects continuing interest from healthtech investors in device-assisted cancer treatments that aim to improve existing standards of care.
This financing and the planned US push will be one to watch for observers of UK and European medical-device startups attempting to bridge domestic adoption and US commercialisation.
They've invested in Combat Medical
Get to know these healthtech investors
Click here for a full list of 7,526+ startup investors in the UK